ArticleSchizophrenia bulletin2026
Olanzapine Dosing in Women with First-Episode Psychosis: An Age-Based Proxy for Menopausal Status.
Article in Schizophrenia bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and hypothesisSome women experience their first episode of psychosis (FEP) in mid-to-later life, including around menopause. Emerging evidence suggests reduced treatment response at this time. However, menopause is rarely considered in treatment guidelines. This study examined whether women experiencing FEP after menopause were prescribed higher olanzapine doses than younger women, using age as a proxy for menopausal status. STUDY
designA population-based cohort of individuals aged 18-64 presenting with FEP to a Dublin mental health service over 18 years was analyzed. Participants who received an adequate olanzapine trial (≥6 weeks) for FEP were included. Women were stratified by age: <51 years (assumed premenopausal) and ≥51 years (assumed postmenopausal). Mean maximum daily olanzapine doses were compared. Analyses were repeated in men. STUDY
resultsOf 396 individuals presenting with FEP, 218 met inclusion criteria. Women aged ≥51 (n = 16) received higher olanzapine doses compared to younger women (n = 78) (15.3 mg ± 6.4 vs 12.4 mg ± 5.4; mean difference 2.9 mg, 95% CI, -0.10 to 5.99, one-sided P = .029, d = 0.53). No age-related dose differences were observed in men (n = 124).
conclusionsWomen presenting with FEP after assumed menopause were prescribed higher olanzapine doses than younger women. This finding should be interpreted cautiously due to the small sample size and inference of menopausal status from age. However, this aligns with emerging evidence suggesting antipsychotic response may reduce following menopause. If replicated, these findings may have important clinical implications for guiding psychosis treatment in mid-life women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.